Moffitt Cancer Center | Strategic Alliance Partners

March 31, 2020

Ken Shain, MD, PhD, discusses isatuximab-irfc and its potential to move into different stages of the multiple myeloma paradigm following further clinical investigation.

March 03, 2020

Jeannie Chern, MD, discusses challenges with germline molecular testing for patients with ovarian cancer.

February 26, 2020

Andrew T. Kuykendall, MD, discusses the additionof fedratinib to the treatment paradigm in myelofibrosis.

February 26, 2020

Mitchel Hoffman, MD, gynecologic oncologist, Moffitt Cancer Center, discusses ongoing research regarding neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian cancer.

February 26, 2020

Robert M. Wenham, MD, gynecologic oncologist and chair of the Gynecologic Oncology Program at Moffitt Cancer Center, discusses data with intraperitoneal (IP) chemotherapy, dose-dense chemotherapy, and intravenous (IV) chemotherapy in patients with advanced ovarian cancer.

February 21, 2020

Andrew T. Kuykendall, MD, discusses the toxicity profiles of ruxolitinib and fedratinib in myelofibrosis.

February 20, 2020

Hye Sook Chon, MD, gynecologic oncologist, Moffitt Cancer Center, discusses challenges that are still faced in the maintenance setting in advanced ovarian cancer.

February 20, 2020

Mitchel Hoffman, MD, gynecologic oncologist, Moffitt Cancer Center, discusses eligibility criteria for primary debulking surgery versus neoadjuvant chemotherapy in advanced ovarian cancer.

February 19, 2020

Robert M. Wenham, MD, gynecologic oncologist and chair of the Department of Gynecologic Oncology at Moffitt Cancer Center, sheds light on the debate between neoadjuvant chemotherapy and primary debulking surgery in patients with newly diagnosed, advanced ovarian cancer.

February 18, 2020

Jeannie Chern, MD, a gynecologic oncologist at Moffitt Cancer Center, discusses important germline and somatic mutations to be aware of in ovarian cancer.

January 25, 2020

Manish Kohli, MD, discusses drugs that have been evaluated in metastatic castration-resistant prostate cancer.

December 18, 2019

Richard Kim, MD, discusses the use of immunotherapy in colorectal cancer.

December 13, 2019

Richard Kim, MD, discusses how molecular profiling can be used to optimize outcomes in patients with metastatic colorectal cancer.

November 16, 2019

Richard Kim, MD, discusses treatment options for BRAF-mutant colon cancer.

October 17, 2019

Andrew T. Kuykendall, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis.

October 02, 2019

Rutika Mehta, MD, MPH, discusses a phase II trial that will combine ramucirumab with TAS-102 in patients with advanced gastric and gastroesophageal junction cancer.

October 01, 2019

Alberto Chiappori, MD, discusses emerging biomarkers in non–small cell lung cancer and the different ways to test for them.

September 25, 2019

Manish Kohli, MD, discusses the challenges of molecular classification in prostate cancer.

September 24, 2019

Rutika Mehta, MD, MPH, gastrointestinal medical oncologist, Moffitt Cancer Center, discusses recent progress that has been made in advanced gastric cancer.

September 21, 2019

Bijal D. Shah, MD, associate professor, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of CAR T-cell therapy in patients with pediatric acute lymphoblastic leukemia (ALL).